Sonata vs. Dayvigo

See how Sonata and Dayvigo compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Sonata is a short-acting nonbenzodiazepine hypnotic best suited for trouble falling asleep, while Dayvigo's orexin-blocking mechanism is approved for both falling asleep and staying asleep.

  • Both carry a boxed warning for complex sleep behaviors like sleep-walking or sleep-driving and are Schedule IV controlled substances with dependence potential.

  • Sonata has decades of generic use and a lower price, while Dayvigo is newer, brand-only, and backed by 12-month trial data on sustained effect.

Sonata vs. Dayvigo Drug Summary

Sonata

Sonata (zaleplon) is a nonbenzodiazepine sedative-hypnotic approved for short-term treatment of insomnia in adults. It is taken as an oral capsule at bedtime, and its very short half-life means some people can take it in the middle of the night if at least 4 hours of sleep time remain.

Dayvigo

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved for insomnia in adults who have trouble falling asleep, staying asleep, or both. It is taken as a single oral tablet each night, usually starting at the lowest effective dose.

Sonata vs. Dayvigo Side Effects

Sonata

Most common
headache (up to 28%)
somnolence (up to 5%)
nausea (up to 7%)
dizziness (up to 7%)

Dayvigo

Most common
headache (up to 6%)
somnolence (up to 10%)
diarrhea (up to 3%)
nasopharyngitis (up to 3%)

Sonata vs. Dayvigo Dosage

Sonata

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once nightly At the start
Maximum dose 20 mg once nightly If needed
Dose changes 2 increases As tolerated

Dayvigo

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once nightly At the start
Maximum dose 10 mg once nightly If needed
Dose changes 1 increase As tolerated

Sonata vs. Dayvigo Indications

Sonata

Sonata is FDA-approved only for short-term insomnia treatment in adults who have trouble falling asleep. It is not intended for long-term nightly use or for children and adolescents under 18.

  • Short-term treatment of insomnia in adults

  • Helps people fall asleep faster

  • Not approved for chronic nightly use

  • Not approved for patients under 18

Dayvigo

Dayvigo is FDA-approved for adults with insomnia marked by trouble falling asleep, staying asleep, or both. Its efficacy has been studied over a full year, supporting more sustained nightly use than some other hypnotics.

  • Insomnia with difficulty falling and/or staying asleep

  • Supported by 12-month trial data

  • Not approved for narcolepsy

  • Not approved for pediatric patients

Sonata vs. Dayvigo Pros and Cons

Sonata

Sonata's ultra-short half-life makes it useful for occasional middle-of-the-night waking, and its metabolism through aldehyde oxidase means fewer drug interactions than many other hypnotics. It is generic and widely available, but it is approved only for short-term use and may not help much with staying asleep through the night.

Pros

  • Very short half-life allows middle-of-night dosing if 4+ hours remain

  • Fewer drug interactions due to non-CYP metabolism

  • Roughly $25 to $115 per month generic, before insurance

  • Decades of real-world use since its 1999 approval

Cons

  • Approved for short-term use only, not chronic nightly treatment

  • Contains tartrazine dye, a risk for allergic reactions in sensitive people

  • Short duration may not help with staying asleep through the night

  • Requires lower dose in elderly, liver impairment, or with cimetidine

Dayvigo

Dayvigo's orexin-blocking mechanism is approved for both falling asleep and staying asleep, with 12-month trial data supporting continued use without rebound insomnia. It has no generic version yet, so out-of-pocket costs run higher, and it requires caution with certain CYP3A-affecting medications.

Pros

  • Approved for both falling asleep and staying asleep

  • 12-month trial data show sustained effect without rebound insomnia

  • Orexin-blocking mechanism differs from GABA-based hypnotics

  • Simple two-dose regimen with no titration needed

Cons

  • Roughly $135 to $400 per month, with no generic version yet

  • Must avoid strong or moderate CYP3A inhibitors/inducers

  • Carries a warning for possible worsening of depression or suicidal thoughts

  • Less real-world history, approved more recently in 2019

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.